Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LEONEL REYES JR.

Allopathic & Osteopathic Physicians Family Medicine

NPI
1841302049
CMS profile
220107
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$382.31

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $382.31 5

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LEONEL REYES JR.

NPI 1841302049 · CMS profile ID 220107

Allopathic & Osteopathic Physicians / Family Medicine

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841302049?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LEONEL REYES JR., NPI 1841302049, CMS profile ID 220107. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841302049?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). LEONEL REYES JR., NPI 1841302049, CMS profile ID 220107. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841302049?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
LEONEL REYES JR., NPI 1841302049, CMS profile ID 220107, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1841302049?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $382.31 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $122.0712/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659868157 CMS
Allergan Inc. $20.0111/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671011193 CMS
AstraZeneca Pharmaceuticals LP $124.9911/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685640837 CMS
Allergan Inc. $102.4810/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671011187 CMS
Merck Sharp & Dohme Corporation $12.7610/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695795151 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $382.31 5
PY2020 $516.96 25
PY2021 $254.93 16
PY2022 $565.96 18
PY2023 $1,847.77 31
PY2024 $2,875.29 31
PY2025 $3,306.12 27

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $755,211.02 111
PY2024 Recipient $1,229.18 7
PY2024 Principal investigator $859,657.92 144
PY2023 Recipient $884.12 7
PY2023 Principal investigator $2,118,069.52 144
PY2022 Recipient $3,289.97 13
PY2022 Principal investigator $555,785.63 62

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

75 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $147.34 12/31/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 914596613
Principal investigator 1 Janssen Research & Development, LLC $12.15 12/27/2022 Non-covered Recipient Entity
Sun Rsrch Inst
CNTO1959CRD3004 No dispute reported 06/30/2026 885236893
Principal investigator 1 PFIZER INC. $14,230.00 12/24/2022 Non-covered Recipient Entity
Sun Research Institute LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 949775359
Principal investigator 1 ABBVIE INC. $1,941.76 12/22/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889826841
Principal investigator 1 ABBVIE INC. $247.00 12/22/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY) No dispute reported 06/30/2026 889826843
Principal investigator 1 ABBVIE INC. $1,425.92 12/14/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889825157
Principal investigator 1 ABBVIE INC. $2,000.00 12/07/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate No dispute reported 06/30/2026 889823651
Principal investigator 1 ABBVIE INC. $698.00 12/07/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate No dispute reported 06/30/2026 889823653
Principal investigator 1 ABBVIE INC. $856.60 12/07/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate No dispute reported 06/30/2026 889823655
Recipient GlaxoSmithKline, LLC. $132.02 12/02/2022 Covered Recipient Physician A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1128518412
Recipient GlaxoSmithKline, LLC. $188.02 12/02/2022 Covered Recipient Physician A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1128518414
Recipient GlaxoSmithKline, LLC. $648.63 12/02/2022 Covered Recipient Physician A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1128518416
Recipient GlaxoSmithKline, LLC. $43.90 12/02/2022 Covered Recipient Physician A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1128518418
Recipient GlaxoSmithKline, LLC. $61.01 12/02/2022 Covered Recipient Physician A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1128518420
Recipient GlaxoSmithKline, LLC. $282.81 12/02/2022 Covered Recipient Physician A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1128518422
Recipient GlaxoSmithKline, LLC. $92.22 12/02/2022 Covered Recipient Physician A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1128518424
Principal investigator 1 ABBVIE INC. $545.30 11/29/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY) No dispute reported 06/30/2026 889822037
Principal investigator 1 ABBVIE INC. $2,714.24 11/29/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889822039
Principal investigator 1 ModernaTX, Inc. $1,800.00 11/18/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963688733
Principal investigator 1 PFIZER INC. $1,512.81 11/17/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 949778823
Principal investigator 1 PFIZER INC. $825.62 11/17/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 949778825
Principal investigator 1 PFIZER INC. $821.96 11/17/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 949778827
Principal investigator 1 PFIZER INC. $12,270.30 11/17/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 949778857
Principal investigator 1 ModernaTX, Inc. $1,600.00 11/09/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963688741
Principal investigator 1 ModernaTX, Inc. $1,700.00 11/09/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963688743
Principal investigator 1 ModernaTX, Inc. $1,650.00 11/09/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963688745
Principal investigator 1 ModernaTX, Inc. $1,650.00 11/09/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963688747
Principal investigator 1 ModernaTX, Inc. $700.00 11/09/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963688749
Principal investigator 1 ModernaTX, Inc. $744.80 11/09/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963688751
Principal investigator 1 ModernaTX, Inc. $800.00 11/02/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963688735
Principal investigator 1 ModernaTX, Inc. $800.00 11/02/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963688737
Principal investigator 1 ModernaTX, Inc. $560.00 11/02/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963688739
Principal investigator 1 ModernaTX, Inc. $3,000.00 11/02/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963688753
Principal investigator 1 ABBVIE INC. $545.30 11/01/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate No dispute reported 06/30/2026 889817783
Principal investigator 1 ModernaTX, Inc. $14,515.63 10/28/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963688725
Principal investigator 1 PFIZER INC. $1,450.00 10/27/2022 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949792741
Principal investigator 1 ModernaTX, Inc. $1,700.00 10/26/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963688727
Principal investigator 1 ModernaTX, Inc. $931.00 10/26/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963688731
Principal investigator 1 ModernaTX, Inc. $9,931.75 10/14/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963688723
Principal investigator 1 PFIZER INC. $9,977.20 10/14/2022 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949792743
Principal investigator 1 ABBVIE INC. $5,242.88 10/13/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889815371
Principal investigator 1 ModernaTX, Inc. $5,189.05 10/05/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963688721
Principal investigator 1 ModernaTX, Inc. $111.87 10/03/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 963688729
Principal investigator 1 PFIZER INC. $27,377.70 09/30/2022 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949792395
Principal investigator 1 PFIZER INC. $67,035.00 09/24/2022 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949792397
Recipient Novo Nordisk AS $35.82 09/14/2022 Covered Recipient Physician Not supplied No dispute reported 06/30/2026 897051461
Recipient Novo Nordisk AS $451.30 09/14/2022 Covered Recipient Physician Not supplied No dispute reported 06/30/2026 897067025
Recipient Novo Nordisk AS $23.00 09/14/2022 Covered Recipient Physician Not supplied No dispute reported 06/30/2026 897109323
Recipient Novo Nordisk AS $58.75 09/14/2022 Covered Recipient Physician Not supplied No dispute reported 06/30/2026 897119839
Recipient Novo Nordisk AS $772.49 09/14/2022 Covered Recipient Physician Not supplied No dispute reported 06/30/2026 897200009
Recipient Novo Nordisk AS $500.00 09/14/2022 Covered Recipient Physician Not supplied No dispute reported 06/30/2026 897203061
Principal investigator 1 ABBVIE INC. $1,228.32 09/07/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889808391
Principal investigator 1 Bausch Health US, LLC $1,700.00 08/30/2022 Non-covered Recipient Entity
Sun Research Institute, LLC
A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel-group Study of the Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C) No dispute reported 06/30/2026 960342917
Principal investigator 1 ABBVIE INC. $1,397.40 08/23/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate No dispute reported 06/30/2026 889807403
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,251.33 08/19/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 914592147
Principal investigator 1 ABBVIE INC. $6,464.64 08/10/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889804175
Principal investigator 1 ABBVIE INC. $1,397.40 08/04/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY) No dispute reported 06/30/2026 889803485
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,985.90 07/22/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19 No dispute reported 06/30/2026 914594591
Principal investigator 1 ABBVIE INC. $1,236.48 07/13/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889800421
Principal investigator 1 ABBVIE INC. $1,397.40 06/23/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate No dispute reported 06/30/2026 889796945
Principal investigator 1 ABBVIE INC. $2,527.36 06/09/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889794789
Principal investigator 1 ABBVIE INC. $4,688.64 05/10/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889790679
Principal investigator 1 AstraZeneca Pharmaceuticals LP $299,173.90 04/22/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061) for Pre-exposure Prophylaxis of COVID-19 No dispute reported 06/30/2026 914597987
Principal investigator 1 ABBVIE INC. $1,282.60 04/21/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate No dispute reported 06/30/2026 889788235
Principal investigator 1 ABBVIE INC. $1,268.00 04/13/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate No dispute reported 06/30/2026 889785543
Principal investigator 1 ABBVIE INC. $4,718.08 04/06/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889783749
Principal investigator 1 ABBVIE INC. $2,829.20 03/30/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate No dispute reported 06/30/2026 889782719
Principal investigator 1 ABBVIE INC. $1,444.60 03/15/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY) No dispute reported 06/30/2026 889780967
Principal investigator 1 ABBVIE INC. $910.00 02/23/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY) No dispute reported 06/30/2026 889778335
Principal investigator 1 ABBVIE INC. $1,280.00 02/23/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY) No dispute reported 06/30/2026 889778337
Principal investigator 1 ABBVIE INC. $780.00 02/15/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate (SELECT-EARLY) No dispute reported 06/30/2026 889777083
Principal investigator 1 ABBVIE INC. $2,080.00 02/15/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate (SELECT-EARLY) No dispute reported 06/30/2026 889777085
Principal investigator 1 ABBVIE INC. $856.60 02/15/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate (SELECT-EARLY) No dispute reported 06/30/2026 889777087
Principal investigator 1 ABBVIE INC. $1,444.60 02/10/2022 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY) No dispute reported 06/30/2026 889776569
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $182.00 01/06/2022 Non-covered Recipient Entity
Sun Research Institute
Phase II Study SLE - A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BMS-986256 in Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 933191543